Ockham

Michael Enright has been appointed president of OckhamCRO, effective immediately. Mr. Enright will provide senior-level leadership and perspective to pharmaceutical, biotechnology and medical device clients for the company’s Phase I-IV clinical operations globally. He will also be responsible for driving overall corporate performance with a customer-centric focus.

He has more than 15 years of experience in financial project management and surveying of the biotechnology and pharmaceutical markets. Previously, Mr. Enright served as Ockham’s chief financial officer, where he successfully helped navigate the merger between Atlantic Search Group and Ockham Development Group.

Ockham’s chief executive officer, James Baker said, “Ockham is very excited to have an experienced, well-rounded leader to assume the OckhamCRO leadership role. With Mike leading the CRO, we are one step closer to achieving our goal to be the number one, global oncology CRO in the next few years.”